MorphoSys granted Progenika's Proteomika S.L. subsidiary non-exclusive, worldwide rights to seven antibodies derived from MorphoSys' HuCAL GOLD and HuCAL PLATINUM antibody technologies

MorphoSys AG

Germany / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Progenika Biopharma S.A.

Spain / Medical Devices and Diagnostics

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced